

Druggable Targets of Squamous Cell Lung Cancer

Cheol Hyeon Kim, M.D.

Division of Pulmonology, Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Korea

Knowledge of molecular pathogenesis of non-small cell lung cancer has increased remarkably and changed the principles of treatment, especially during the past decade. These advancements have been limited mainly to adenocarcinoma of the lung. Recently, genetic alterations in squamous cell lung cancer (SQCLC) have been detailed and positive results of clinical trials using agents targeting these changes have indicated the potential for improved treatment outcomes for SQCLC.

Keywords: Carcinoma, Squamous Cell; Lung Neoplasms

Introduction

Knowledge of molecular pathogenesis of non-small cell lung cancer (NSCLC) has increased remarkably and changed principles of treatment especially for the past ten years. These changes are, however, limited mainly to adenocarcinoma of the lung. At this time, driver mutations can be identified in most cases of lung adenocarcinoma and targeted drugs like gefitinib, erlotinib, and crizotinib can be applied to about one third of the patients¹.

Recently, genetic alterations in squamous cell lung cancer (SQCLC) have been studied extensively² and are attracting attention because mutations, which have a critical role in the development of SQCLC and are frequently found in patients, can become targets of anti-cancer chemotherapy.

Clinical Characteristics of SQCLC

SQCLC now comprises about 30% of NSCLC but was the most common subtype of NSCLC in Korea. Patients with SQCLC usually complain cough, dyspnea, or hemoptysis. Tumors tend to be located in the central airways and are easy to form cavities. SQCLC is very strongly associated with smoking. Generally, SQCLC advances locally and shows fewer distant metastases than adenocarcinoma of the lung. In pathology, well-differentiated SQCLC characteristically shows keratinisation, intercellular bridges, and pearl formation. p63 is positive and thyroid transcription factor 1 is negative on immunohistochemistry examination of SQCLC³.

Pathogenesis of SQCLC

Pathogenesis of SQCLC seems to be different from that of adenocarcinoma, considering that there is a big difference in response to targeted therapies between the two types of NSCLC. Sequential pathogenesis of SQCLC is well known. Bronchial epithelial cells exposed to smoking for a long time develop to basal cell hyperplasia, squamous metaplasia, squamous dysplasia, carcinoma in situ, and finally squamous cell carcinoma. Together with these morphologic changes, chromosomal abnormalities, especially loss of heterozygosity, are accumulated during the process of carcinogenesis³.

Address for correspondence: Cheol Hyeon Kim, M.D.

Department of Internal Medicine, Korea Cancer Center Hospital, 75 Nowon-ro, Nowon-gu, Seoul 139-706, Korea

Phone: 82-2-970-1209, **Fax:** 82-2-970-2438

E-mail: cheol@kcch.re.kr

Received: Jul. 29, 2013

Revised: Aug. 6, 2013

Accepted: Aug. 12, 2013

©It is identical to the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>).

Copyright © 2013

The Korean Academy of Tuberculosis and Respiratory Diseases.

All rights reserved.




Figure 1. Frequencies of targetable genetic alterations found in squamous cell lung cancer. *FGFR1*: fibroblast growth factor receptor 1; *DDR2*: discoidin domain receptor 2; *PI3KCA*: phosphoinositide 3-kinase catalytic subunit.

Genetic Alterations Found in SQCLC

Genetic alterations found frequently in SQCLC can be classified as follows (Figure 1)⁴.

1. Membrane receptor alterations

1) Fibroblast growth factor receptor 1 (*FGFR1*) amplification: *FGFR* is a transmembrane receptor tyrosine kinase, involved in embryonal development, cell proliferation, cell differentiation, and regulation of angiogenesis. There are four kinds of members in *FGFR* family, and 22 fibroblast growth factor (FGF) ligands are known. It is known that activation of this pathway leads to enhanced growth of NSCLC cells (Figure 2) and that increased blood level and tissue expression of FGF is associated with a poor prognosis⁵.

Amplification of *FGFR1*, located in 8p12, was first reported as an important genetic change in SQCLC in 2010. Weiss et al.⁶ reported that 22% of 153 SQCLC tissues showed *FGFR1* amplification by fluorescence *in situ* hybridization analysis. Dutt et al.⁷ identified *FGFR1* amplification in 21% of 57 SQCLC samples and in 3% of adenocarcinomas of the lung by single nucleotide polymorphism array analysis. Both studies showed that growth of cell with *FGFR1* amplification depends on *FGFR1*. Further, Weiss et al.⁶ showed treatment of PD173074, an inhibitor of *FGFR*, decreased tumor mass in a mouse model.

2) Discoidin domain receptor (*DDR*) 2 mutation: *DDR*, a receptor tyrosine kinase, plays a role in cell adhesion, proliferation, and extracellular remodeling after binding of collagen, an endogenous ligand (Figure 2). It was reported that upregulation of *DDR1* was related to prolonged disease-free and overall survival of patients with NSCLC, especially SQCLC⁸.




Figure 2. Signaling pathways involved in genetic alterations present in squamous cell lung cancer. *FGFR1*: fibroblast growth factor receptor 1; *DDR2*: discoidin domain receptor 2; *PI3K*: phosphoinositide 3-kinase; *PTEN*: phosphatase and tensin homolog.

Mutations of *DDR1* and *DDR2*, located in 1q23, have been found in SQCLC. Hammerman and coworkers reported that the frequency of *DDR2* mutation was 3.8%, when they examined 290 SQCLC tissues and cell lines by DNA sequencing analysis. The mutations of *DDR2* are activating mutations, and the activation was inhibited by treatment with dasatinib, a multi-kinase inhibitor. Further, they represented a SQCLC patient with a wild type *EGFR* who showed radiological response after treatment with both dasatinib and erlotinib in their clinical trial. The patient was confirmed to have a new mutation (S768R) in the *DDR2* kinase domain⁹.

3) *MET* amplification: *MET* gene is located in 7q31 and expresses a receptor tyrosine kinase for hepatocyte growth factor. Overexpression of *MET* causes abnormal cell proliferation and invasion to neighboring tissues (Figure 2)¹⁰. Lung cancer cells with *MET* amplification are known to be very sensitive to crizotinib, an anaplastic lymphoma kinase/*MET* inhibitor. According to a previous report, *MET* amplification is more common in SQCLC than in other types of NSCLC and is associated with a poor prognosis¹⁰. Spiegel et al.¹¹ reported that MetMab, a monoclonal antibody against *MET*, in combination with erlotinib showed a benefit in progression-free survival (2.9 months vs. 1.5 months, $p=0.04$) and overall survival (12.6 months vs. 3.8 months, $p=0.002$) compared with erlotinib alone in a *MET*-overexpressed subgroup of advanced NSCLC patients in a randomized phase II study.

2. Signaling pathway alterations

1) Phosphoinositide 3-kinase catalytic subunit α (*PIK3CA*) amplification and mutation: *PIK3CA*, located in 3q26, encodes a class I phosphoinositide 3-kinase (PI3K) α catalytic

subunit (p110 α). It is well known that PI3K-AKT pathway plays a critical role in survival and growth of diverse cancer cells (Figure 2)¹⁰. Both copy-number gain and mutations of *PI3K* are found in lung cancer. The copy-number gain of *PI3K* is found in 33.1% of SQCLC, in 6.2% of adenocarcinoma, and in 4.7% of small cell lung cancer. The mutations of *PI3K* are found in 6.5% of SQCLC and in 1.5% of adenocarcinoma⁴. Inhibitors of this pathway are in development and clinical trials using many kinds of PI3K inhibitors are ongoing for patients with SQCLC.

2) AKT1 mutation: E17K somatic mutation of *AKT1*, located in 14q32, activates the protein kinase continuously. This mutation is known to be present in about 1% of SQCLC but not in adenocarcinoma¹⁰. Akt inhibitors are currently being studied in several phase II trials.

3) Phosphatase and tensin homolog (PTEN) loss: *PTEN*, a tumor suppressor gene located in 10q23, encodes a lipid phosphatase inhibiting PI3K-AKT pathway and loss of PTEN activates PI3K-AKT signaling (Figure 2)¹⁰. Inactivation of PTEN by somatic *PTEN* deletions, mutations, and epigenetic mechanisms is found in many cancers. Reduction or loss of PTEN expression has been reported in up to 70% of NSCLC, both adenocarcinoma and SQCLC. *PTEN* mutations, occurring in approximately 5% of lung cancers, are significantly associated with squamous cell rather than adenocarcinoma histology (10.2% vs. 1.7%)³. Lung cancers with PTEN loss may be more sensitive to inhibitors of the PI3K pathway and clinical trials of PI3K inhibitors for cancers with PTEN loss are ongoing.

4) BRAF mutation: BRAF is a cytoplasmic serine/threonine kinase which plays an important role in the RAS-mitogen-activated protein kinase (MAPK) pathway (Figure 2). *BRAF* gene is located in 7q34. Mutation of *BRAF* causes increased kinase activity and consequently activates MAPK. The mutations of *BRAF* are found in ~2% of SQCLC and adenocarcinoma of the lung⁴. Selective inhibitors of *BRAF* are undergoing clinical trials now.

3. Transcriptional factor alterations

1) p53 mutation: *p53*, a tumor suppressor gene, is located in chromosome 17p13 and encodes a protein functioning mainly as a transcriptional factor which regulates the transcription of genes related to cell cycle arrest, apoptosis, and DNA repair. *p53* mutations are found in more than half of NSCLC and in about 65% of SQCLC. Mutational hotspots are concentrated in the sequence-specific DNA-binding domain. Approximately 75% of mutations are missense mutations and lead to loss of function as a transcription factor. The mutations are affected by smoking. In a substantial number of tumors, wild-type *p53* is inactivated by overexpression or amplification of *MDM2* which ubiquitinates *p53* and marks it for degradation. Treatment with adenoviral vector was tried in the past

but clinical trials using small molecules are now ongoing.

2) SOX2 amplification: Amplification of chromosome 3q26 is a kind of the most common genetic alterations found in SQCLC. *SOX2* is a candidate oncogene present in this locus and amplification of *SOX2* has been reported in about 20% of SQCLC. *SOX2* is a transcriptional factor which plays an important role in regulation of stem cell function and development of lung epithelium¹⁰. Bass et al.¹² showed that inhibition of *SOX2* suppressed cell growth. But following studies confirmed that *SOX2* amplification is not enough for carcinogenesis in itself and additional mutations of downstream effectors are needed to make a cancer. Clinical trials with *SOX2* inhibitors are not ongoing.

4. Ongoing clinical trials using targeted drugs in SQCLC

Clinical trials of new therapies to some of the targets described are already underway for the treatment of SQCLC (Table 1). Those for FGFR1 are in progress most actively.

Goss et al.¹³ are reported interim analysis of a phase II/III study of cediranib vs. placebo in combination with carboplatin and paclitaxel as initial therapy for 251 NSCLC patients. Cediranib (Recentin; AstraZeneca, Luton, UK) is an oral small molecule tyrosine inhibitor that inhibits vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factors receptors (PDGFRs), c-kit, and FGFR1. The result showed improved responses in the cediranib arm (38% vs. 16%, $p=0.001$), although this study was stopped due to excess toxicities, including hypertension, hypothyroidism, hand-foot syndrome, and gastrointestinal toxicity on the cediranib arm. A study with a lower dose of cediranib has been initiated.

Reck et al.¹⁴ reported a randomized phase II trial with BIBF 1120 (Boehringer Ingelheim, Ingelheim am Rhein, Germany), an oral small molecule inhibitor of FGFRs, PDGFRs, and VEGFRs. In their trial conducted in advanced NSCLC ($n=73$) after failure of platinum-based chemotherapy, 48% of patients treated with BIBF 1120 reached stable disease and the median progression-free survival was 6.9 weeks. Toxicities were manageable, with liver enzyme elevations, diarrhea, nausea, vomiting, and abdominal pain being the most common. Now, two phase III trials that compared BIBF1120 to placebo in addition to either docetaxel or pemetrexed as second-line treatments are underway.

Altorki et al.¹⁵ reported a multicenter, open-label, phase II "window of opportunity" trial with pazopanib (Votrient; GlaxoSmithKline, Brentford, UK), another oral small molecule inhibitor of the VEGFRs, PDGFRs, c-kit, and FGFRs. In the trial of 2 to 6 weeks of treatment with pazopanib in clinical stage I, II NSCLC ($n=26$), 86% of patients had some tumor reduction, with three partial responses. Pazopanib was well tolerated in this study, with the most common adverse events being hypertension, diarrhea, and fatigue. Phase II/III clinical trials of pazopanib in NSCLC are ongoing (NCT01208064,

Table 1. Drugs targeting driver mutations in squamous cell lung cancer

Compound	Target	Type of agent	Monotherapy/ Combined therapy	Phase of clinical trial	NCTID
FGFR1					
BGJ398	Pan FGFR	Kinase inhibitor	Monotherapy	1	NCT01004224
AZD4547	Pan FGFR	Kinase inhibitor	Monotherapy	1	NCT00979134
E-3810	Pan FGFR, VEGFR	Kinase inhibitor	Monotherapy	1	NCT01283945
FP-1039	FGF	Antibody	Monotherapy	1	NCT00687505
TKI258	FGFR, VEGFR, PDGFR	Kinase inhibitor	Monotherapy	1	NCT01270906
BIBF 1120	FGFR, VEGFR, PDGFR	Kinase inhibitor	Combined therapy	2	NCT01346540
DDR2					
Dasatinib	BCR/ABL, SRC, c-Kit, DDR1-2	Kinase inhibitor	Monotherapy	2	NCT00787267 NCT00459342 NCT01514864
BRAF					
GSK2118436	BRAF	Kinase inhibitor	Monotherapy	2	NCT01336634
PI3KCA					
PF-04691502	PI3K, mTOR	Kinase inhibitor	Monotherapy	1	NCT00927823
XL147	PI3K	Kinase inhibitor	Combined therapy	1	NCT00756847
BKM120	PI3K	Kinase inhibitor	Monotherapy	2	NCT01297491
BYL719	PI3K	Kinase inhibitor	Monotherapy	1	NCT01219699
XL765	PI3K, mTOR	Kinase inhibitor	Monotherapy	1	NCT00485719
PX866	PI3K	Kinase inhibitor	Combined therapy	1	NCT01204099
GDC-0941	PI3K	Kinase inhibitor	Combined therapy	1	NCT00975182
AKT1					
MK2206	Pan AKT	Kinase inhibitor	Combined therapy Combined therapy	1 2	NCT01147211 NCT01294306
GDC-0068	Pan AKT	Kinase inhibitor	Monotherapy	1	NCT01090960
MET					
Crizotinib	MET, ALK	Kinase inhibitor	Monotherapy Combined therapy	1	NCT00585195 NCT01121575
XL184	MET, RET, VEGFR2	Kinase inhibitor	Combined therapy Combined therapy	2	NCT00940225 NCT00596648
MetMab	MET	Antibody	Combined therapy	3	NCT01456325
Arq197	MET	Kinase inhibitor	Combined therapy	2	NCT01395758
IGF-1R					
AXL1717	IGF-1R	Kinase inhibitor	Monotherapy	1	NCT01561456
CP-751, 871	IGF-1R	Kinase inhibitor	Combined therapy	1	NCT00596830
AMG 479	IGF-1R	Antibody	Combined therapy	2	NCT00807612

NCTID: National Cancer Trial Identification; FGFR1: fibroblast growth factor receptor 1; VEGFR: vascular endothelial growth factor receptor; PDGFR: platelet-derived growth factors receptor; DDR2: discoidin domain receptor 2; PI3KCA: phosphoinositide 3-kinase catalytic subunit α ; PI3K: phosphoinositide 3-kinase; mTOR: mammalian target of rapamycin; ALK: anaplastic lymphoma kinase; IGF: insulin-like growth factor.

NCT00775307).

Conclusion

Although adenocarcinoma is now the most common type of lung cancer, SQCLC still occupies a major part of lung cancer. However, targeted therapeutic drugs against SQCLC are not developed until now unfortunately. In case of adenocarcinoma, targeted therapy was developed through basic researches on carcinogenesis, translational researches, and clinical trials and molecular classification, as well as pathologic classification of cancers, became critical during this process. Recently, more and more genetic alterations of SQCLC have been identified and positive results of clinical trials using agents targeting these changes attract our attention.

Acknowledgements

This work is supported by a grant (50452-2013) from the Korea Institute of Radiological and Medical Sciences Research Fund (RTR).

References

1. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. *Lancet Oncol* 2011;12:175-80.
2. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. *Nature* 2012;489:519-25.
3. Drilon A, Rekhtman N, Ladanyi M, Paik P. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. *Lancet Oncol* 2012;13:e418-26.
4. Perez-Moreno P, Brambilla E, Thomas R, Soria JC. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. *Clin Cancer Res* 2012;18:2443-51.
5. Semrad TJ, Mack PC. Fibroblast growth factor signaling in non-small-cell lung cancer. *Clin Lung Cancer* 2012;13:90-5.
6. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal *FGFR1* amplification associates with therapeutically tractable *FGFR1* dependency in squamous cell lung cancer. *Sci Transl Med* 2010;2:62ra93.
7. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, et al. Inhibitor-sensitive *FGFR1* amplification in human non-small cell lung cancer. *PLoS One* 2011;6:e20351.
8. Ford CE, Lau SK, Zhu CQ, Andersson T, Tsao MS, Vogel WF. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. *Br J Cancer* 2007;96:808-14.
9. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, et al. Mutations in the *DDR2* kinase gene identify a novel therapeutic target in squamous cell lung cancer. *Cancer Discov* 2011;1:78-89.
10. Heist RS, Sequist LV, Engelman JA. Genetic changes in squamous cell lung cancer: a review. *J Thorac Oncol* 2012;7:924-33.
11. Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAB or placebo in combination with erlotinib in advanced NSCLC. *J Clin Oncol* 2011;29(Suppl):7505.
12. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. *SOX2* is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. *Nat Genet* 2009;41:1238-42.
13. Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. *J Clin Oncol* 2010;28:49-55.
14. Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. *Ann Oncol* 2011;22:1374-81.
15. Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. *J Clin Oncol* 2010;28:3131-7.